Generic-drug strategy is a needle-in-a-haystack problem

Generic-drug strategy is a needle-in-a-haystack problem. Which molecules? Which formulations? What's the bioequivalence risk? What's the patent and pricing exposure? Teams answer these by reading, modelling and running experiments, slowly and at cost.

The strategy got harder

Patent cliffs, pricing pressure and policy shifts can materially change the value of a program. A promising molecule on paper can look very different once market timing and access are considered together.

That turns portfolio selection into a high-stakes prediction problem: which programs survive contact with reality? The winners won't be the fastest filers; they'll be the best at choosing what to file.

Freedom to operate is the first filter

Before formulation, before bioequivalence, before a single batch: a program only matters if the molecule is actually clear to make and sell in the markets you care about. Get that wrong and every downstream dollar is spent on a launch that can't happen.

Yet freedom to operate is the hardest thing to check quickly. The answer is spread across patent registers, approval databases and opposition records, one portal per country. So most teams skip a proper screen and rank the pipeline on gut feel, or pay for a formal legal opinion on a handful of candidates and guess at the rest.

That's the gap Patriage is built to close: a pre-FTO screen that reads a molecule's global patent estate and the public drug registers and shows when each market opens, who already sells it, and what could trip it up, so you prioritise with evidence, not gut feel, and commission the expensive legal work only where it counts.

What it does, and what it doesn't

It narrows the haystack. It doesn't replace patent counsel or a formal freedom-to-operate opinion.

A pre-FTO screen doesn't remove the scientist, the patent attorney or the regulator. It removes wasted cycles on programs that were never going to win, and tells you where to point the people whose time is worth the most.